InMed Pharmaceuticals Achieves 2g/L Cannabinoid Yield with IntegraSyn™
VANCOUVER, BC – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol (“CBN”), today… Read More




